Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database
Abstract
Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious
bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or
haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users.
Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline
during 2009–2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS).
Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905
patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for
pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups.
Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they
were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or
cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients.
Keywords
Cilostazol; Peripheral artery disease; Primary healthcare
Bibliographic citation
Real J, Serna C, Giner-Soriano M, Forés R, Pera G, Ribes E, et al. Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. BMC Cardiovascular Disorders 2018 May 8;18(1):85. doi: 10.1186/s12872-018-0822-4.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3519This item appears in following collections
The following license files are associated with this item: